|
1
|
Imenez Silva PH, Unwin R, Hoorn EJ, et al:
Acidosis, cognitive dysfunction and motor impairments in patients
with kidney disease. Nephrol Dial Transplant. 37 (Suppl
2):ii4–ii12. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zoccali C and Capasso G: Genetic
biomarkers of cognitive impairment and dementia of potential
interest in CKD patients. J Nephrol. 37:2473–2479. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jabbari B and Vaziri ND: The nature,
consequences, and management of neurological disorders in chronic
kidney disease. Hemodial Int. 22:150–160. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kim DS, Kim SW and Gil HW: Emotional and
cognitive changes in chronic kidney disease. Korean J Intern Med.
37:489–501. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chu NM, Hong J, Harasemiw O, Chen X,
Fowler KJ, Dasgupta I, Bohm C, Segev DL and McAdams-DeMarco MA;
Global Renal Exercise Network, : Chronic kidney disease, physical
activity and cognitive function in older adults-results from the
National Health and Nutrition Examination Survey (2011–2014).
Nephrol Dial Transplant. 37:2180–2189. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Khatri M, Ryan CM, Gao X, de Boer IH,
Braffett BH, Molitch M, Karger AB, Lorenzi GM, Lee P, Trapani VR,
et al: CKD associates with cognitive decline in Middle-Aged and
older adults with Long-Standing Type 1 diabetes. Kidney 360.
4:1058–1071. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jerjes W: The importance of attentive
primary care in the early identification of mild cognitive
impairment: Case series. AME Case Rep. 8:562024. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Voorend CGN, van Buren M, Berkhout-Byrne
NC, Kerckhoffs APM, van Oevelen M, Gussekloo J, Richard E, Bos WJW
and Mooijaart SP: Apathy Symptoms, physical and cognitive function,
Health-related quality of life, and mortality in older patients
with CKD: A longitudinal observational study. Am J Kidney Dis.
83:162–172.e1. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Palmer S, Vecchio M, Craig JC, Tonelli M,
Johnson DW, Nicolucci A, Pellegrini F, Saglimbene V, Logroscino G,
Fishbane S and Strippoli GF: Prevalence of depression in chronic
kidney disease: Systematic review and meta-analysis of
observational studies. Kidney Int. 84:179–191. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bahall M, Legall G and Lalla C: Depression
among patients with chronic kidney disease, associated factors, and
predictors: A cross-sectional study. BMC Psychiatry. 23:7332023.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Crews DC, Campbell KN, Liu Y, Bussue O,
Dawkins I and Young BA: Chronic kidney disease and risk factor
prevalence in Saint Kitts and Nevis: A cross-sectional study. BMC
Nephrol. 18:72017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vanent KN, Leasure AC, Acosta JN, Kuohn
LR, Woo D, Murthy SB, Kamel H, Messé SR, Mullen MT, Cohen JB, et
al: Association of chronic kidney disease with risk of
intracerebral hemorrhage. JAMA Neurol. 79:911–918. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhu J, Fu Y, Olovo CV, Xu J, Wu Q, Wei W,
Jiang K and Zheng X: The influence of gut microbiota on the
gut-brain-kidney axis and its implications for chronic kidney
disease. Front Microbiol. 16:15353562025. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xie Z, Tong S, Chu X, Feng T and Geng M:
Chronic kidney disease and cognitive impairment: The Kidney-brain
axis. Kidney Dis (Basel). 8:275–285. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bugnicourt JM, Godefroy O, Chillon JM,
Choukroun G and Massy ZA: Cognitive disorders and dementia in CKD:
The neglected kidney-brain axis. J Am Soc Nephrol. 24:353–363.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tsuruya K and Yoshida H: Cognitive
impairment and brain atrophy in patients with chronic kidney
disease. J Clin Med. 13:14012024. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lopez-Vargas PA, Tong A, Howell M and
Craig JC: Educational interventions for patients with CKD: A
systematic review. Am J Kidney Dis. 68:353–370. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nocito C, Lubinsky C, Hand M, Khan S,
Patel T, Seliga A, Winfield M, Zuluaga-Ramirez V, Fernandes N, Shi
X, et al: Centrally acting angiotensin-converting enzyme inhibitor
suppresses type I interferon responses and decreases inflammation
in the periphery and the CNS in Lupus-prone mice. Front Immunol.
11:5736772020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gordon FJ, Brody MJ, Fink GD, Buggy J and
Johnson AK: Role of central catecholamines in the control of blood
pressure and drinking behavior. Brain Res. 178:161–173. 1979.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Viggiano D, Wagner CA, Martino G,
Nedergaard M, Zoccali C, Unwin R and Capasso G: Mechanisms of
cognitive dysfunction in CKD. Nat Rev Nephrol. 16:452–469. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Imenez Silva PH, Pepin M, Figurek A,
Gutiérrez-Jiménez E, Bobot M, Iervolino A, Mattace-Raso F, Hoorn
EJ, Bailey MA, Hénaut L, et al: Animal models to study cognitive
impairment of chronic kidney disease. Am J Physiol Renal Physiol.
326:F894–F916. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Murtaza A and Dasgupta I: Chronic kidney
disease and cognitive impairment. J Stroke Cerebrovasc Dis.
30:1055292021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Choi B, Crouzet C, Lau WL, Cribbs DH and
Fisher MJ: Cerebral blood flow in chronic kidney disease. J Stroke
Cerebrovasc Dis. 30:1057022021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fu EL, Desai RJ, Paik JM, Kim DH, Zhang Y,
Mastrorilli JM, Cervone A and Lin KJ: Comparative safety and
effectiveness of warfarin or rivaroxaban versus apixaban in
patients with advanced CKD and atrial fibrillation: Nationwide US
cohort study. Am J Kidney Dis. 83:293–305.e1. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kelly DM, Georgakis MK, Franceschini N,
Blacker D, Viswanathan A and Anderson CD: Interplay Between chronic
kidney disease, hypertension, and stroke: Insights from a
multivariable mendelian randomization analysis. Neurology.
101:e1960–e1969. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kurella Tamura M, Xie D, Yaffe K, Cohen
DL, Teal V, Kasner SE, Messé SR, Sehgal AR, Kusek J, DeSalvo KB, et
al: Vascular risk factors and cognitive impairment in chronic
kidney disease: The Chronic Renal Insufficiency Cohort (CRIC)
study. Clin J Am Soc Nephrol. 6:248–256. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pei X, Bakerally NB, Wang Z, Bo Y, Ma Y,
Yong Z, Zhu S, Gao F, Bei Z and Zhao W: Kidney function and
cognitive impairment: A systematic review and meta-analysis. Ren
Fail. 47:24635652025. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Peritoneal Dialysis Adequacy 2006 Work
Group, : Clinical practice guidelines for hemodialysis adequacy,
update 2006. Am J Kidney Dis. 48 (Suppl):S2–S90. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nagy E, Tharwat S, Elsayed AM, Shabaka SAE
and Nassar MK: Anxiety and depression in maintenance hemodialysis
patients: Prevalence and their effects on health-related quality of
life. Int Urol Nephrol. 55:2905–2914. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Adejumo OA, Edeki IR, Sunday Oyedepo D,
Falade J, Yisau OE, Ige OO, Adesida AO, Daniel Palencia H, Sabri
Moussa A, Abdulmalik J, et al: Global prevalence of depression in
chronic kidney disease: A systematic review and meta-analysis. J
Nephrol. 37:2455–2472. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Krishnan AV, Phoon RK, Pussell BA,
Charlesworth JA, Bostock H and Kiernan MC: Altered motor nerve
excitability in end-stage kidney disease. Brain. 128:2164–2174.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Laaksonen S, Metsärinne K, Voipio-Pulkki
LM and Falck B: Neurophysiologic parameters and symptoms in chronic
renal failure. Muscle Nerve. 25:884–890. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Baumgaertel MW, Kraemer M and Berlit P:
Neurologic complications of acute and chronic renal disease. Handb
Clin Neurol. 119:383–393. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lambourg E, Colvin L, Guthrie G, Murugan
K, Lim M, Walker H, Boon G and Bell S: The prevalence of pain among
patients with chronic kidney disease using systematic review and
meta-analysis. Kidney Int. 100:636–649. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jasti DB, Mallipeddi S, Apparao A,
Vengamma B, Sivakumar V and Kolli S: A clinical and
electrophysiological study of peripheral neuropathies in
predialysis chronic kidney disease patients and relation of
severity of peripheral neuropathy with degree of renal failure. J
Neurosci Rural Pract. 8:516–524. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Aggarwal HK, Sood S, Jain D, Kaverappa V
and Yadav S: Evaluation of spectrum of peripheral neuropathy in
predialysis patients with chronic kidney disease. Ren Fail.
35:1323–1329. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Araujo SM, de Bruin VM, Nepomuceno LA,
Maximo ML, Daher Ede F, Correia Ferrer DP and de Bruin PF: Restless
legs syndrome in end-stage renal disease: Clinical characteristics
and associated comorbidities. Sleep Med. 11:785–790. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Aritake-Okada S, Nakao T, Komada Y, Asaoka
S, Sakuta K, Esaki S, Nomura T, Nakashima K, Matsuura M and Inoue
Y: Prevalence and clinical characteristics of restless legs
syndrome in chronic kidney disease patients. Sleep Med.
12:1031–1033. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
DeFerio JJ, Govindarajulu U, Brar A, Cukor
D, Lee KG and Salifu MO: Association of restless legs syndrome and
mortality in end-stage renal disease: An analysis of the United
States Renal Data System (USRDS). BMC Nephrol. 18:2582017.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Arnold R, Issar T, Krishnan AV and Pussell
BA: Neurological complications in chronic kidney disease. JRSM
Cardiovasc Dis. 5:20480040166776872016.PubMed/NCBI
|
|
41
|
Masson P, Webster AC, Hong M, Turner R,
Lindley RI and Craig JC: Chronic kidney disease and the risk of
stroke: A systematic review and meta-analysis. Nephrol Dial
Transplant. 30:1162–1169. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kurella Tamura M, Yaffe K, Hsu CY, Yang J,
Sozio S, Fischer M, Chen J, Ojo A, DeLuca J, Xie D, et al:
Cognitive impairment and progression of CKD. Am J Kidney Dis.
68:77–83. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Formiga F, Badía-Tejero AM, Corsonello A,
Ärnlöv J, Carlsson AC, Mattace-Raso F, Tap L, Kostka T, Guligowska
A, Sieber CC, et al: Diabetes and factors associated with cognitive
and functional decline. The screening for CKD among older people
across Europe (SCOPE) study. Aging Clin Exp Res. 35:2693–2701.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Tap L, Corsonello A, Formiga F,
Moreno-Gonzalez R, Ärnlöv J, Carlsson AC, Roller-Wirnsberger R,
Wirnsberger G, Ziere G, Freiberger E, et al: Is kidney function
associated with cognition and mood in late life?: The Screening for
CKD among Older People across Europe (SCOPE) study. BMC Geriatr. 20
(Suppl 1):S2972020. View Article : Google Scholar
|
|
45
|
Hobson P, Kumwenda M, Shrikanth S, Nair H
and Wong S: Risk and incidence of cognitive impairment in patients
with chronic kidney disease and diabetes: The results from a
longitudinal study in a community cohort of patients and an age and
gender-matched control cohort in North Wales, UK. BMJ Open.
12:e0530082022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Li T, Hu Z, Qiao L, Wu Y and Ye T: Chronic
kidney disease and cognitive performance: NHANES 2011–2014. BMC
Geriatr. 24:3512024. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Li C, Mao W and Liu X: Depression, anxiety
and reduced quality of life in predialysis: Differences across the
CKD stages? Int J Clin Pract. 68:657–658. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lefrère A, Burtey S, Bobot S, Belzeaux R
and Bobot M: Depression in chronic kidney disease: Particularities,
specific mechanisms and therapeutic considerations, a narrative
review. Behav Brain Res. 483:1154672025. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bezerra CIL, Silva BC and Elias RM:
Decision-making process in the pre-dialysis CKD patients: Do
anxiety, stress and depression matter? BMC Nephrol. 19:982018.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Elorza CLC, Santos Junior AD and Celeri
EHRV: Quality of life, depression and anxiety in children and
adolescents with CKD and their primary caregivers. J Bras Nefrol.
45:335–343. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Gadia P, Awasthi A, Jain S and Koolwal GD:
Depression and anxiety in patients of chronic kidney disease
undergoing haemodialysis: A study from western Rajasthan. J Family
Med Prim Care. 9:4282–4286. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Lai YR, Cheng BC, Huang CC, Chiu WC, Tsai
NW, Chen JF and Lu CH: Correlation between kidney and peripheral
nerve functions in Type 2 diabetes. QJM. 113:173–180. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Roytman S, Paalanen N, Carli G, Marusic U,
Kanel P, van Laar T and Bohnen NI: Multisensory mechanisms of gait
and balance in Parkinson's disease: An integrative review. Neural
Regen Res. 20:82–92. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Balaj AR and Kaku H: A novel approach to
Parkinson's disease treatment with a potentially dual-acting
therapeutic agent that targets α-synuclein aggregation and neuron
death. Neural Regen Res. 19:2577–2578. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Meléndez-Flores JD and Estrada-Bellmann I:
Linking chronic kidney disease and Parkinson's disease: A
literature review. Metab Brain Dis. 36:1–12. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Kwon MJ, Kim JK, Kim JH, Kim JH, Kim MJ,
Kim NY, Choi HG and Kim ES: Exploring the Link between chronic
kidney disease and Parkinson's disease: Insights from a
longitudinal study using a national health screening cohort.
Nutrients. 15:32052023. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Liu X, Ou YN, Ma YH, Huang LY, Zhang W and
Tan L: Renal function and neurodegenerative diseases: A two-sample
Mendelian randomization study. Neurol Res. 45:456–464. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Nam GE, Kim NH, Han K, Choi KM, Chung HS,
Kim JW, Han B, Cho SJ, Jung SJ, Yu JH, et al: Chronic renal
dysfunction, proteinuria, and risk of Parkinson's disease in the
elderly. Mov Disord. 34:1184–1191. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Huang ZH, Chen HC, Chou YC, Lin CL, Kao
CH, Lo HY, Yang TY and Liu FC: Does nephrotic syndrome without
chronic kidney disease increase the risk of Parkinson's disease and
secondary Parkinsonism? A nationwide population-based study in
Taiwan. BMJ Open. 8:e0208212018. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Safarpour Y, Vaziri ND and Jabbari B:
Movement disorders in chronic kidney disease-A descriptive review.
J Stroke Cerebrovasc Dis. 30:1054082021. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Miwa K and Toyoda K: Covert vascular brain
injury in chronic kidney disease. Front Neurol. 13:8245032022.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Miglinas M, Cesniene U, Janusaite MM and
Vinikovas A: Cerebrovascular disease and cognition in chronic
kidney disease patients. Front Cardiovasc Med. 7:962020. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Greco F, Quarta LG, Parizel PM, Zobel BB,
Quattrocchi CC and Mallio CA: Relationship between chronic kidney
disease and cerebral white matter hyperintensities: A systematic
review. Quant Imaging Med Surg. 13:7596–7606. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Heinze M, Schell M, Mayer C, Nägele FL,
Petersen M, Alba Schmidt E, Schmidt IM, Cheng B, Huber TB, Thomalla
G and Schmidt-Lauber C: Kidney function and cerebral small vessel
disease. Am J Kidney Dis. 86:136–138. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Seliger SL and Sarnak MJ: Subclinical
vascular disease of the brain in dialysis patients. Am J Kidney
Dis. 50:8–10. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Kobayashi S, Ikeda T, Moriya H, Ohtake T
and Kumagai H: Asymptomatic cerebral lacunae in patients with
chronic kidney disease. Am J Kidney Dis. 44:35–41. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Shima H, Ishimura E, Naganuma T, Ichii M,
Yamasaki T, Mori K, Nakatani T and Inaba M: Decreased kidney
function is a significant factor associated with silent cerebral
infarction and periventricular hyperintensities. Kidney Blood Press
Res. 34:430–438. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Yang J, Chen X, Cao X, Yang H, Liu P, Yin
X, Zhang X and Chen Z: Chronic kidney disease as a catalyst for
cerebral microbleeds: Understanding the underlying mechanisms and
treatment approaches. Front Med (Lausanne). 12:15786662025.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Lau WL, Nunes ACF, Vasilevko V, Floriolli
D, Lertpanit L, Savoj J, Bangash M, Yao Z, Shah K, Naqvi S, et al:
Chronic kidney disease increases cerebral microbleeds in mouse and
man. Transl Stroke Res. 11:122–134. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Lin X, Liang W, Li L, Xiong Q, He S, Zhao
J, Guo X, Xiang S, Zhang P, Wang H, et al: The accumulation of gut
Microbiome-derived indoxyl sulfate and P-Cresyl sulfate in patients
with End-stage renal disease. J Ren Nutr. 32:578–586. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Wang Q, Han Y, Pang L, Zhou Z and Dai L:
Gut microbiome remodeling in chronic kidney disease: Implications
of kidney replacement therapies and therapeutic interventions.
Front Med (Lausanne). 12:16202472025. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Banoglu E, Jha GG and King RS: Hepatic
microsomal metabolism of indole to indoxyl, a precursor of indoxyl
sulfate. Eur J Drug Metab Pharmacokinet. 26:235–240. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Brito JS, Borges NA, Anjos JSD, Nakao LS,
Stockler-Pinto MB, Paiva BR, Cardoso-Weide LC, Cardozo LFMF and
Mafra D: Aryl hydrocarbon receptor and uremic toxins from the gut
microbiota in chronic kidney disease patients: Is there a
relationship between them? Biochemistry. 58:2054–2060. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Ohtsuki S, Asaba H, Takanaga H, Deguchi T,
Hosoya K, Otagiri M and Terasaki T: Role of blood-brain barrier
organic anion transporter 3 (OAT3) in the efflux of indoxyl
sulfate, a uremic toxin: Its involvement in neurotransmitter
metabolite clearance from the brain. J Neurochem. 83:57–66. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Adesso S, Magnus T, Cuzzocrea S, Campolo
M, Rissiek B, Paciello O, Autore G, Pinto A and Marzocco S: Indoxyl
sulfate affects glial function increasing oxidative stress and
neuroinflammation in chronic kidney disease: Interaction between
astrocytes and microglia. Front Pharmacol. 8:3702017. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Gondouin B, Cerini C, Dou L, Sallée M,
Duval-Sabatier A, Pletinck A, Calaf R, Lacroix R, Jourde-Chiche N,
Poitevin S, et al: Indolic uremic solutes increase tissue factor
production in endothelial cells by the aryl hydrocarbon receptor
pathway. Kidney Int. 84:733–744. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Yamaguchi K, Yisireyili M, Goto S, Cheng
XW, Nakayama T, Matsushita T, Niwa T, Murohara T and Takeshita K:
Indoxyl sulfate activates NLRP3 inflammasome to induce cardiac
contractile dysfunction accompanied by myocardial fibrosis and
hypertrophy. Cardiovasc Toxicol. 22:365–377. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Shivanna S, Kolandaivelu K, Shashar M,
Belghasim M, Al-Rabadi L, Balcells M, Zhang A, Weinberg J, Francis
J, Pollastri MP, et al: The aryl hydrocarbon receptor is a critical
regulator of tissue factor stability and an antithrombotic target
in uremia. J Am Soc Nephrol. 27:189–201. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Nakano T, Katsuki S, Chen M, Decano JL,
Halu A, Lee LH, Pestana DVS, Kum AST, Kuromoto RK, Golden WS, et
al: Uremic toxin indoxyl sulfate promotes proinflammatory
macrophage activation via the interplay of OATP2B1 and Dll4-Notch
signaling. Circulation. 139:78–96. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Hill ZR, Flynn CK and Adams JB: Indoxyl
sulfate and autism spectrum disorder: A literature review. Int J
Mol Sci. 25:129732024. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Gryp T, Vanholder R, Vaneechoutte M and
Glorieux G: p-Cresyl Sulfate. Toxins (Basel). 9:522017. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Cosola C, Rocchetti MT, Cupisti A and
Gesualdo L: Microbiota metabolites: Pivotal players of
cardiovascular damage in chronic kidney disease. Pharmacol Res.
130:132–142. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Watanabe H, Sakaguchi Y, Sugimoto R,
Kaneko K, Iwata H, Kotani S, Nakajima M, Ishima Y, Otagiri M and
Maruyama T: Human organic anion transporters function as a
high-capacity transporter for p-cresyl sulfate, a uremic toxin.
Clin Exp Nephrol. 18:814–820. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Shah SN, Knausenberger TB, Pontifex MG,
Connell E, Le Gall G, Hardy TAJ, Randall DW, McCafferty K, Yaqoob
MM, Solito E, et al: Cerebrovascular damage caused by the gut
microbe/host co-metabolite p-cresol sulfate is prevented by
blockade of the EGF receptor. Gut Microbes. 16:24316512024.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Bertarini L, Imbeni F, Brighenti V,
Martusciello I, Pellati F and Alboni S: Para-Cresol and the brain:
Emerging role in neurodevelopmental and neurodegenerative disorders
and therapeutic perspectives. ACS Pharmacol Transl Sci.
8:3432–3452. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Wu IW, Lin CY, Chang LC, Lee CC, Chiu CY,
Hsu HJ, Sun CY, Chen YC, Kuo YL, Yang CW, et al: Gut microbiota as
diagnostic tools for mirroring disease progression and circulating
Nephrotoxin levels in chronic kidney disease: Discovery and
validation study. Int J Biol Sci. 16:420–434. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Zhu Y, Li Q and Jiang H: Gut microbiota in
atherosclerosis: Focus on trimethylamine N-oxide. Apmis.
128:353–366. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Liu Y, Zhang HY, Hong XY, Wu YX, Li MJ and
Zheng HJ: Trimethylamine N-oxide induced cognitive impairment
through disruption of blood-brain barrier by inhibiting TGF-β
pathway. Chem Biol Interact. 424:1118622026. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Ge P, Duan H, Tao C, Niu S, Hu Y, Duan R,
Shen A, Sun Y and Sun W: TMAO promotes NLRP3 inflammasome
activation of microglia aggravating neurological injury in ischemic
stroke through FTO/IGF2BP2. J Inflamm Res. 16:3699–3714. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Vogt NM, Romano KA, Darst BF, Engelman CD,
Johnson SC, Carlsson CM, Asthana S, Blennow K, Zetterberg H,
Bendlin BB and Rey FE: The gut microbiota-derived metabolite
trimethylamine N-oxide is elevated in Alzheimer's disease.
Alzheimers Res Ther. 10:1242018. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Wang QJ, Shen YE, Wang X, Fu S, Zhang X,
Zhang YN and Wang RT: Concomitant memantine and Lactobacillus
plantarum treatment attenuates cognitive impairments in APP/PS1
mice. Aging (Albany NY). 12:628–649. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Hoyles L, Pontifex MG, Rodriguez-Ramiro I,
Anis-Alavi MA, Jelane KS, Snelling T, Solito E, Fonseca S, Carvalho
AL, Carding SR, et al: Regulation of blood-brain barrier integrity
by microbiome-associated methylamines and cognition by
trimethylamine N-oxide. Microbiome. 9:2352021. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Freedman BI, Sink KM, Hugenschmidt CE,
Hughes TM, Williamson JD, Whitlow CT, Palmer ND, Miller ME, Lovato
LC, Xu J, et al: Associations of early kidney disease with brain
magnetic resonance imaging and cognitive function in African
Americans with type 2 diabetes mellitus. Am J Kidney Dis.
70:627–637. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Tamura MK, Pajewski NM, Bryan RN, Weiner
DE, Diamond M, Van Buren P, Taylor A, Beddhu S, Rosendorff C,
Jahanian H, et al: Chronic kidney disease, cerebral blood flow, and
white matter volume in hypertensive adults. Neurology.
86:1208–1216. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Lau WL, Huisa BN and Fisher M: The
Cerebrovascular-Chronic kidney disease connection: Perspectives and
mechanisms. Transl Stroke Res. 8:67–76. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Qiu Y, Lv X, Su H, Jiang G, Li C and Tian
J: Structural and functional brain alterations in end stage renal
disease patients on routine hemodialysis: A voxel-based morphometry
and resting state functional connectivity study. PLoS One.
9:e983462014. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Clingan MJ, Zhang Z, Caserta MP, Cox KL,
Gupta V, Baumgarten DA, Zhai QJ and Alexander LF: Imaging patients
with kidney failure. Radiographics. 43:e2201162023. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Zemp DD, Giannini O, Quadri P, Rabuffetti
M, Tettamanti M and de Bruin ED: Gait disorders in CKD patients:
Muscle wasting or cognitive impairment? A cross-sectional pilot
study to investigate gait signatures in Stage 1–5 CKD patients. BMC
Nephrol. 23:722022. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Koren MJ, Blumen HM, Ayers EI, Verghese J
and Abramowitz MK: Cognitive dysfunction and gait abnormalities in
CKD. Clin J Am Soc Nephrol. 16:694–704. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Ho JQ, Verghese J and Abramowitz MK:
Walking while talking in older adults with chronic kidney disease.
Clin J Am Soc Nephrol. 15:665–672. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Axelsson T, Zetterberg H, Blennow K,
Arslan B, Ashton NJ, Axelsson M, Svensson MK, Saeed A and Guron G:
Plasma concentrations of neurofilament light, p-Tau231 and glial
fibrillary acidic protein are elevated in patients with chronic
kidney disease and correlate with measured glomerular filtration
rate. BMC Nephrol. 26:2312025. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Cao Y, Wang Z, Xue J, Wang L, Qin W, Sun Q
and Chang J: Chronic Kidney disease and cognitive frailty in aging:
Molecular crosstalk and clinical implications. Front Aging
Neurosci. 18:17785742026. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Wang T, Tang S, Zheng R and Wang L:
Exploring the potential relationship between kidney disease index
and cognitive dysfunction: A machine learning approach with NHANES
data. BMC Geriatr. 25:6642025. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Cao M, Tang B, Yang L and Zeng JL: Machine
learning-based prediction model for cognitive impairment risk in
patients with chronic kidney disease. PLoS One. 20:e03246322025.
View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Wang YF, Mao L, Chen HJ, Yang YT, Li XL,
Lu GM, Xing W and Zhang LJ: Predicting cognitive impairment in
chronic kidney disease patients using structural and functional
brain network: An application study of artificial intelligence.
Prog Neuropsychopharmacol Biol Psychiatry. 122:1106772023.
View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Iwata Y, Nakade Y, Kinoshita M, Sabit H,
Nakajima R, Furuichi K, Mita M, Nakane M, Sakai N, Kitajima S, et
al: Intra-brain and plasma levels of L-Serine are associated with
cognitive status in patients with chronic kidney disease. Kidney
Dis (Basel). 9:118–129. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Lambert JC, Heath S, Even G, Campion D,
Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ,
Tavernier B, et al: Genome-wide association study identifies
variants at CLU and CR1 associated with Alzheimer's disease. Nat
Genet. 41:1094–1099. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
108
|
Andrade A, Bachmann M, Bobot M, Bruchfeld
A, Fridolin I, Mani LY and Xu H; CONNECT Action (Cognitive Decline
in Nephro-Neurology European Cooperative Target) collaborators, :
Cognitive impairment in chronic kidney disease: Role of brain
imaging, functional imaging, electroencephalography, cerebrospinal
fluid biomarkers and sensors. Nephrol Dial Transplant. 40
(Suppl_2):ii18–ii27. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Drew DA, Weiner DE and Sarnak MJ:
Cognitive impairment in CKD: Pathophysiology, management, and
prevention. Am J Kidney Dis. 74:782–790. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Tungsanga S, Treewatchareekorn S,
Kulvichit W, Katavetin P and Leelahavanichkul A: Effects of
Lactobacillus rhamnosus GG on Gut-derived uremic toxins and
gut microbiome in Non-dialysis CKD patients: FR-PO970. J Am Soc
Nephrol. 34:6752023. View Article : Google Scholar
|
|
111
|
de Faria Barros A, Borges NA, Nakao LS,
Dolenga CJ, do Carmo FL, de Carvalho Ferreira D, Stenvinkel P,
Bergman P, Lindholm B and Mafra D: Effects of probiotic
supplementation on inflammatory biomarkers and uremic toxins in
non-dialysis chronic kidney patients: A double-blind, randomized,
placebo-controlled trial. J Functional Foods. 46:378–383. 2018.
View Article : Google Scholar
|
|
112
|
Vaziri ND, Yuan J, Khazaeli M, Masuda Y,
Ichii H and Liu S: Oral activated charcoal adsorbent (AST-120)
ameliorates chronic kidney disease-induced intestinal epithelial
barrier disruption. Am J Nephrol. 37:518–525. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Yoshifuji A, Wakino S, Irie J, Matsui A,
Hasegawa K, Tokuyama H, Hayashi K and Itoh H: Oral adsorbent
AST-120 ameliorates gut environment and protects against the
progression of renal impairment in CKD rats. Clin Exp Nephrol.
22:1069–1078. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Six I, Gross P, Rémond MC, Chillon JM,
Poirot S, Drueke TB and Massy ZA: Deleterious vascular effects of
indoxyl sulfate and reversal by oral adsorbent AST-120.
Atherosclerosis. 243:248–256. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Ohtake T, Mochida Y, Ishioka K, Moriya H,
Hidaka S, Hirata M, Yamada H, Kumagai H and Kobayashi S:
Improvement of microcirculatory impairment in patients with
predialysis chronic kidney disease after AST-120 administration.
Renal Replac Ther. 6:282020. View Article : Google Scholar
|
|
116
|
Schulman G, Berl T, Beck GJ, Remuzzi G,
Ritz E, Arita K, Kato A and Shimizu M: Randomized
Placebo-controlled EPPIC trials of AST-120 in CKD. J Am Soc
Nephrol. 26:1732–1746. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Cha RH, Kang SW, Park CW, Cha DR, Na KY,
Kim SG, Yoon SA, Han SY, Chang JH, Park SK, et al: A randomized,
controlled trial of oral intestinal sorbent AST-120 on renal
function deterioration in patients with advanced renal dysfunction.
Clin J Am Soc Nephrol. 11:559–567. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Cedillo-Flores R, Cuevas-Budhart MA,
Cavero-Redondo I, Kappes M, Ávila-Díaz M and Paniagua R: Impact of
gut microbiome modulation on uremic toxin reduction in chronic
kidney disease: A systematic review and network Meta-analysis.
Nutrients. 17:12472025. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Biancone L, Bruno S, Deregibus MC, Tetta C
and Camussi G: Therapeutic potential of mesenchymal stem
cell-derived microvesicles. Nephrol Dial Transplant. 27:3037–3042.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Himanshu Gunjan Pandey RP, Mukherjee R and
Chang CM: Meta-analysis study of the therapeutic impact of
Mesenchymal stem cells derived exosomes for chronic kidney
diseases. Biochem Biophys Rep. 43:1020722025.PubMed/NCBI
|
|
121
|
Cao Q, Huang C, Chen XM and Pollock CA:
Mesenchymal Stem Cell-derived exosomes: Toward Cell-free
therapeutic strategies in chronic kidney disease. Front Med
(Lausanne). 9:8166562022. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Lee JH, Yoon YM and Lee SH: TUDCA-Treated
mesenchymal stem cells protect against ER stress in the hippocampus
of a murine chronic kidney disease model. Int J Mol Sci.
20:6132019. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Morizane A, Doi D, Kikuchi T, Okita K,
Hotta A, Kawasaki T, Hayashi T, Onoe H, Shiina T, Yamanaka S and
Takahashi J: Direct comparison of autologous and allogeneic
transplantation of iPSC-derived neural cells in the brain of a
non-human primate. Stem Cell Reports. 1:283–292. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Freedman B: Modeling kidney disease with
iPS cells. Biomark Insights. 10 (Suppl 1):S153–S169.
2015.PubMed/NCBI
|
|
125
|
Jovanovich N, Habib A, Kodavali C, Edwards
L, Amankulor N and Zinn PO: The evolving role of induced
pluripotent stem cells and cerebral organoids in treating and
modeling neurosurgical diseases. World Neurosurg. 155:171–179.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Doss MX and Sachinidis A: Current
challenges of iPSC-Based disease modeling and therapeutic
implications. Cells. 8:4032019. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Chao CT and Lin SH: Uremic toxins and
frailty in patients with chronic kidney disease: A molecular
insight. Int J Mol Sci. 22:62702021. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Daga S, Donati F, Capitani K, Croci S,
Tita R, Giliberti A, Valentino F, Benetti E, Fallerini C, Niccheri
F, et al: New frontiers to cure Alport syndrome: COL4A3 and COL4A5
gene editing in podocyte-lineage cells. Eur J Hum Genet.
28:480–490. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Kang S, Park SJ, Lee MH, Kronbichler A and
Shin JI: CRISPR-Cas9 system in autosomal dominant polycystic kidney
disease: A comprehensive review. Child Kidney Dis. 29:4–11. 2025.
View Article : Google Scholar
|
|
130
|
Xiang T, Luo X, Ye L, Huang H and Wu Y:
Klotho alleviates NLRP3 inflammasome-mediated neuroinflammation in
a temporal lobe epilepsy rat model by activating the Nrf2 signaling
pathway. Epilepsy Behav. 128:1085092022. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Kantor B, O'Donovan B and Chiba-Falek O:
Trends and challenges of AAV-delivered gene editing therapeutics
for CNS disorders: Implications for neurodegenerative disease. Mol
Ther Nucleic Acids. 36:1026352025. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Ren D, Fisson S, Dalkara D and Ail D:
Immune responses to gene editing by viral and Non-viral delivery
vectors used in retinal gene therapy. Pharmaceutics. 14:19732022.
View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Gil JS, Lee S and Koo T: Therapeutic in
vivo genome editing: Innovations and challenges in rAAV
vector-based CRISPR delivery. Gene Ther. 33:97–106. 2026.
View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Taha EA, Lee J and Hotta A: Delivery of
CRISPR-Cas tools for in vivo genome editing therapy: Trends and
challenges. J Control Release. 342:345–361. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Wang D, Tai PWL and Gao G:
Adeno-associated virus vector as a platform for gene therapy
delivery. Nat Rev Drug Discov. 18:358–378. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Garrigues S, Peng M, Kun RS and de Vries
RP: Non-homologous end-joining-deficient filamentous fungal strains
mitigate the impact of off-target mutations during the application
of CRISPR/Cas9. mBio. 14:e00668232023. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Charlesworth CT, Deshpande PS, Dever DP,
Camarena J, Lemgart VT, Cromer MK, Vakulskas CA, Collingwood MA,
Zhang L, Bode NM, et al: Identification of preexisting adaptive
immunity to Cas9 proteins in humans. Nat Med. 25:249–254. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Yin H, Xue W, Chen S, Bogorad RL,
Benedetti E, Grompe M, Koteliansky V, Sharp PA, Jacks T and
Anderson DG: Genome editing with Cas9 in adult mice corrects a
disease mutation and phenotype. Nat Biotechnol. 32:551–553. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Zhao R, Wang C, Li J, Liao Y, Huang C, Hu
T, Zhang H and Zhang W: DNA and RNA editing for the therapy of
human diseases: Current status, challenges, and future prospects.
Mol Biomed. 7:552026. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Walters L, Cook-Deegan RM and Adashi EY:
Governing heritable human genome editing: A Textual history and a
proposal for the future. CRISPR J. 4:469–476. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Stone D, Aubert M and Jerome KR:
Adeno-associated virus vectors and neurotoxicity-lessons from
preclinical and human studies. Gene Ther. 32:60–73. 2025.
View Article : Google Scholar : PubMed/NCBI
|
